Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.07.2020 | Case report

Camrelizumab/rivoceranib

Various toxicities: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Meng M, et al. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. Journal of Cancer Research and Therapeutics 16: 327-334, No. 2, Apr 2020. Available from: URL: http://doi.org/10.4103/jcrt.JCRT_101_20 Meng M, et al. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. Journal of Cancer Research and Therapeutics 16: 327-334, No. 2, Apr 2020. Available from: URL: http://​doi.​org/​10.​4103/​jcrt.​JCRT_​101_​20
Metadaten
Titel
Camrelizumab/rivoceranib
Various toxicities: 4 case reports
Publikationsdatum
01.07.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-80302-2

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Imatinib

Case report

Ciclosporin

Case report

Blinatumomab